Seven new medicines recommended for European approval
Includes antibiotics treatments and medicines for haemostasis and HIV
Seven new medicines have been recommended for approval at the January 2015 meeting of the Committee for Medicinal Products for Human Use (CHMP).
The committee, which is the safety and efficacy arm of the EMA, has recommended granting a marketing authorisation for liraglutide (Saxenda) for weight management in adults who are obese, or those who are overweight and have one or more complications related to their weight.
The CHMP also gave positive opinions for oritavancin (Orbactiv) and tedizolid phosphate (Sivextro) two antibiotics for the treatment of acute bacterial skin and skin structure infections.
Lamivudine / raltegravir (Dutrebis) was recommended by the committee as a new treatment option for human immunodeficiency virus (HIV-1).
Ciclosporin (Ikervis) was recommended for the treatment of severe keratitis, an eye condition in which the cornea becomes inflamed.
Cangrelor (Kengrexal) received a positive opinion from the Committee for the reduction of thrombotic cardiovascular events whilst human fibrinogen/human thrombin (Raplixa) received a positive opinion as a supportive treatment where standard surgical techniques are insufficient for the improvement of haemostasis.